title: Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
abstract: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
authors.affiliation: Experimental and Clinical Oncology, Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Molin
authors.affiliation: Department of Oncology, Lund University Hospital, Lund, Sweden.
authors.forename: Johan
authors.initials: J
authors.lastname: Linderoth
authors.affiliation: Division of Haematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.|Haematology Centre, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Björn E
authors.initials: BE
authors.lastname: Wahlin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004363:Drug Utilization / Q000639:trends; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012042:Registries; D000069283:Rituximab / Q000008:administration & dosage; D012737:Sex Factors; D013548:Sweden / Q000453:epidemiology
chemical_list: D018951:Antigens, CD20; D000069283:Rituximab
keywords: gender differences; nodular lymphocyte predominant Hodgkin lymphoma; population-based analysis; rituximab; survival